Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Crossflo-retention bonus
1
Jan 19, 2011 05:54PM

I don't know the "mix" of these 9 people, but I don't think it matters whether the outcome is divest, grow or JV...

In any scenario except "close it down" you need to be able to specifiy enhancements/changes, develop them, test them, deploy them and support them.

It is unwise to have developers do the testing.
It is unwise to have developers do the source code builds.

Nothing against 'developers', please understand - I was one myself for many years before moving into executive management. Just that this segregation shows discipline in the SDLC process and gives potential investors a warmer feeling during their "due diligence".

Source code is the ultimate Intellectual Property of this business. A configuration management should be in place to ensure the integrity of the source code, manage versioning, build for test and ultimately package for release. It would be my hope that this mysterious and highly paid Dharmesh Mistry chap has this well under control. If not, they should get someone who understands such things instead.

I fully understand the reason for such "stay put" plans. It may be the only part of PTSC's compensation methodology that I do understand.

Share
New Message
Please login to post a reply